Michelle Longmire isn’t interested in incremental change, she’s aiming instead to cure all disease within two decades. A rather ambitious mission, but her decentralized clinical trial platform might be just what the medical research field needs to speed up the timeline on cure development.
Dr. Longmire is a trained physician, tech founder, and the CEO of Medable, and she is betting that the future of medical research lies not only in the discovery of new therapies, but in radically accelerating the path to get them to patients. Clinical trial research is historically cumbersome and inefficient, but she believes that’s just because it’s outdated.
Her solution to this problem is a technology-first infrastructure that reduces bottlenecks and brings research to people where they live. This removes one of the biggest barriers to clinical trial participation: geography. Aside from the ability to leverage an infinitely larger participant pool, Medable is using AI to cut the administrative work needed for trial deployment in half.
Top 10 pharmaceutical companies are already using this tech to shave weeks off of their build time. The software is rapidly growing in popularity, and could be poised to change the field completely by giving us back one of the most valuable assets we have in healthcare, time.
Solutions for Real-World Problems
Michelle Longmire began her career as a physician scientist specializing in dermatology at
Stanford University, where she later completed her fellowship in biomedical research. Most of her work focused on immunology and clinical trial design, which is what opened her eyes to the inefficiencies of biomedical research, which she saw as potential.
As a physician, she saw how many patients were excluded from participating in clinical trials because of geography, schedule, or lack of access to an academic medical center. Looking at the data through the lens of a scientist, she saw that the data they were collecting didn’t tell the full story because it lacked the diversity and scale to be a representation of the real world. That’s when she started asking herself “what if the clinical trial could come to the patient?” which motivated her to found her company.
Even thinking about bringing the clinical trial to the patient represents a different approach to clinical trials, where they aren’t site-centric, but person-centric. This comes as part of a larger shift in healthcare toward becoming person-centric, where a patient is an active participant in their own care rather than a passive recipient in a provider-driven model.
Medable is now one of the most widely adopted platforms for decentralized trials, powering research across over 60 countries and 300 clinical trials. Under her leadership, Medable has raised $500 million in venture capital and has been recognized by Fast Company as one of the world’s most creative companies. The biggest challenge the company is currently facing is scaling quickly enough to keep up with demand.
The other driving force behind Medable is equity. By creating a platform that reduces the logistical, cultural, and financial burdens of trial participation, she hopes to increase representation in research and generate data that reflects the full spectrum of global human health.
What’s Next
While Dr. Longmire’s vision is ambitious, the results are tangible and measurable. In just a few years, Medable has matured from a startup to one of the most influential platforms in clinical research. They continually churn out new features, from integrations with electronic health records and enhanced AI-powered participant experience tools to expanded language support for over 120 languages, enabling global deployment. These advancements are helping Medable be increasingly seen as a partner to pharmaceutical sponsors looking to modernize their trial infrastructure without compromising compliance or data integrity
Most recently, the company introduced a long-term follow-up model designed specifically for cell and gene therapy trials, one of the most complex and cost-intensive areas of research. The model allows patients to remain in studies for up to 15 years without needing to regularly return to trial sites, reducing barriers to participation while improving data quality and continuity.
The impact of this technology is huge, and it’s meaningful too. Patients who were once excluded because of rural location, disability, caregiving responsibilities, or work constraints now have a pathway to access novel therapies. Trials that once took years to recruit for can now start faster, with higher retention and more representative data. With time, that will translate to faster approvals, more inclusive safety and efficacy data, and a research model that is more equitable.
Longmire thinks that at our current rate of cure development, it will take 200 years to find cures for all diseases. But what if we could reach that in 20 years? With Medable, she’s working to shorten that timeline even further. She thinks 10 years is possible, and she’s building the infrastructure to try.
We can’t solve the world’s biggest health challenges using yesterday’s systems, but if Medable’s trajectory continues, tomorrow’s systems may look a lot more like hers.